Your session is about to expire
← Back to Search
Blood Thinner for Radial Artery Occlusion (CAPITAL-RAPTOR Trial)
CAPITAL-RAPTOR Trial Summary
This trial will test whether a blood thinner can reduce the risk of a common complication from a heart procedure.
CAPITAL-RAPTOR Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCAPITAL-RAPTOR Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CAPITAL-RAPTOR Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My heart's rhythm problems don't improve with treatment.I am scheduled for heart or other surgery within the next 30 days.I have received clot-dissolving medication in the last 24 hours.I cannot take blood thinners due to a high risk of bleeding.My liver is not working well.I need blood thinners for another health condition.I have had a heart vessel examination or treatment through my wrist.I have had or attempted to have a procedure through another artery or vein.I am a woman who can become pregnant and am not using birth control.I am 18 years old or older.I have had bleeding that needed medical care in the last 6 months.I have been diagnosed with antiphospholipid antibody syndrome.I have a noticeable bruise or bleeding concern where my wrist was accessed.I have experienced a severe heart condition that suddenly reduced blood flow.You are allergic to rivaroxaban.You are not expected to live more than 30 days.My kidneys are not working well, with a creatinine clearance under 30mL/min.I use medications like ibuprofen or aspirin.My hemoglobin level is below 10 g/dL without a known cause.I have had a brain bleed in the past.I currently have cancer.I have used IIb/IIIa inhibitors during heart artery procedures.I had a stroke or a mini-stroke in the last 3 months.I am not taking any CYP3A4 or P-glycoprotein inhibitors.Your platelet count is less than 50 billion per liter.
- Group 1: Rivaroxaban
- Group 2: Standard of Care
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA cleared Rivaroxaban 15 MG Oral Tablet [Xarelto] for public use?
"Rivaroxaban 15 MG Oral Tablet [Xarelto] is a Phase 3 trial drug, meaning that there is both evidence of its efficacy and multiple rounds of data indicating its safety. Our team rates it as a 3 on our safety scale."
Are patients currently being accepted into this trial?
"That is accurate. The 1800 patients that this study needs are currently being recruited from 2 clinical sites. Information about the trial was first posted on October 3rd, 2018 and the most recent update occurred on February 8th, 2022."
Does this research mark a new development in medical science?
"Rivaroxaban 15 MG Oral Tablet [Xarelto] has been under clinical study since 2015. The first trial was sponsored by Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma and had 2180 participants. After the initial Phase 3 approval in 2015, there are currently 62 active trials involving Rivaroxaban 15 MG Oral Tablet [Xarelto] being conducted across 45 nations and 403 cities."
What are the standard effects of Rivaroxaban 15 MG Oral Tablet [Xarelto]?
"Rivaroxaban 15 MG Oral Tablet [Xarelto] is an effective medication for the treatment of venous thromboembolism, chronic coronary artery disease, and deep vein thrombosis."
How many people are allowed to take part in this research project at any one time?
"That is correct, the online information hosted on clinicaltrials.gov affirms that this study is still recruiting patients. The details of the posting state that it was put up on October 3rd, 2018 and last updated February 8th, 2022. Currently, the plan is to have 1800 people take part in the trial at 2 locations."
Share this study with friends
Copy Link
Messenger